# REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

> **NCT06041386** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 336 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Mepolizumab
- **OTHER:** Spirometry

## Key facts

- **NCT ID:** NCT06041386
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-20
- **Primary completion:** 2025-01-31
- **Final completion:** 2028-06-14
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041386, "REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06041386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*